Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224548 | 0.85 | TAAR1 (0.72) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL3168355 | 0.82 | BLM (0.74) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL3668004 | 0.82 | BLM (0.74) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| Iodide SCHEMBL29101247 | 0.82 | TAAR1 (0.68) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL10049612 | 0.82 | GFER (0.47) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL6314759 | 0.77 | TAAR1 (0.62) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL143553 | 0.77 | GFER (0.77) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL2642760 | 0.77 | LOXL2 (0.63) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL6532602 | 0.77 | MAOB (0.73) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL6313123 | 0.77 | HTR2A (0.80) | TAAR1HTR2ACYP2A6CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020160075-A1 | CHEMICAL COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-7553971-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| WO-2008027466-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | TAAR1 4767/4885HTR2A 2822/4885CYP2A6 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.